VOTRIENT for Renal cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 105 adverse event reports in the FDA FAERS database where VOTRIENT was used for Renal cell carcinoma.
Most Reported Side Effects for VOTRIENT
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 167 | 27.6% | 167 | 8 |
| Hypertension | 65 | 10.7% | 5 | 28 |
| Nausea | 59 | 9.7% | 9 | 29 |
| Diarrhoea | 54 | 8.9% | 4 | 21 |
| Fatigue | 52 | 8.6% | 10 | 21 |
| Vomiting | 44 | 7.3% | 6 | 26 |
| Decreased appetite | 40 | 6.6% | 6 | 20 |
| Investigation | 40 | 6.6% | 0 | 39 |
| Disease progression | 38 | 6.3% | 24 | 11 |
| Asthenia | 37 | 6.1% | 6 | 19 |
| Malaise | 22 | 3.6% | 3 | 11 |
| Abdominal pain | 20 | 3.3% | 2 | 8 |
| Hair colour changes | 20 | 3.3% | 0 | 7 |
| Platelet count decreased | 20 | 3.3% | 1 | 7 |
| Blood pressure increased | 18 | 3.0% | 2 | 10 |
Other Indications for VOTRIENT
Renal cancer (111)
Product used for unknown indication (97)
Sarcoma (24)
Renal cancer metastatic (22)
Leiomyosarcoma (21)
Metastatic renal cell carcinoma (21)
Neoplasm malignant (21)
Soft tissue sarcoma (16)
Soft tissue cancer (13)
Angiosarcoma (12)
Other Drugs Used for Renal cell carcinoma
CABOZANTINIB S-MALATE (9,156)
NIVOLUMAB (6,514)
LENVATINIB (3,849)
PEMBROLIZUMAB (3,027)
SUNITINIB MALATE (2,926)
PAZOPANIB (2,799)
IPILIMUMAB (2,585)
AXITINIB (2,447)
EVEROLIMUS (1,573)
TIVOZANIB (1,258)